Latest Period
Q2 2026
Security Snapshot
CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value (CBIO) Institutional Ownership
CUSIP: G2545C104
13F Institutional Holders and Ownership History from Q2 2025 to Q2 2026
Institutions Reporting
80
Shares (Excl. Options)
29,113,798
Price
$18.00
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, $0.001 par value
- Symbol
- CBIO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 29,113,798
- Total 13F value
- $524,050,483
- Portfolio coverage rank
- 0%
- Share change
- +4,011,885
- Value change
- +$71,707,307
- Number of holders
- 80
- Shares outstanding
- 39,966,150
- SEC-reported price per share
- $16.43
- Insider filing price
- $16.43
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CBIO - CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value is tracked under CUSIP G2545C104.
- 80 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 59 to 80 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $461,268,042 to $524,050,483.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 80 institutions filings for Q2 2026.
Security key
G2545C104
Latest holder period
Q2 2026
13F holders
80
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
CBIO full holder history
CRESCENT BIOPHARMA, INC. SEC filings
CRESCENT BIOPHARMA, INC. company facts
CRESCENT BIOPHARMA, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G2545C104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
CBIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 17% | -11% | $118,843,344 | +$17,260,668 | 6,602,408 | +17% | Peter Harwin | 16 Jul 2026 |
| FMR LLC | 15% | $49,932,849 | 4,133,514 | FMR LLC | 31 Dec 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 9.5% | $29,460,007 | 2,666,064 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2025 | |||
| ForGrowth III PA B.V. | 6.1% | $21,778,519 | 1,677,852 | ForGrowth III PA B.V. | 08 Dec 2025 | |||
| BALYASNY ASSET MANAGEMENT L.P. | 5.5% | $29,294,640 | 1,510,033 | Balyasny Asset Management L.P. | 31 Mar 2026 | |||
| Vestal Point Capital, LP | 5.4% | $16,575,000 | 1,500,000 | Vestal Point Capital, LP | 31 Dec 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 10% | $18,736,150 | 1,387,863 | BVF PARTNERS L P/IL | 30 Jun 2025 | |||
| TANG CAPITAL MANAGEMENT LLC | 4.2% | -17% | $22,504,000 | +$8,924,000 | 1,160,000 | +66% | TANG CAPITAL MANAGEMENT, LLC | 31 Mar 2026 |
| Logos Global Management LP | 4.1% | $7,762,500 | 575,000 | Logos Global Management LP | 30 Jun 2025 |
As of 30 Jun 2026, 80 institutional investors reported holding 29,113,798 shares of CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value (CBIO). This represents 73% of the company’s total 39,966,150 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
68%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 10% | 4,133,514 | 0% | 0% | $74,403,252 |
| BVF INC/IL | 6.9% | 2,748,763 | 0% | 1.3% | $49,477,734 |
| Fairmount Funds Management LLC | 6.9% | 2,747,866 | 0% | 3.3% | $49,461,588 |
| Venrock Adviser, LLC | 5.3% | 2,133,576 | 0% | 1.2% | $38,404,368 |
| Logos Global Management LP | 4.8% | 1,900,000 | +294% | 1.5% | $34,200,000 |
| FCPM III SERVICES B.V. | 4.2% | 1,677,852 | 0% | 4% | $30,201,336 |
| Balyasny Asset Management L.P. | 4.2% | 1,662,917 | +10% | 0.05% | $29,932,506 |
| Vestal Point Capital, LP | 4.1% | 1,630,000 | +8.7% | 0.69% | $29,340,000 |
| Opaleye Management Inc. | 3.3% | 1,319,351 | +0.51% | 2.2% | $23,748,318 |
| BlackRock, Inc. | 3.2% | 1,271,762 | +999% | 0% | $22,891,716 |
| TANG CAPITAL MANAGEMENT LLC | 2.9% | 1,160,000 | 0% | 0.95% | $20,880,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9% | 767,755 | -4.2% | 0% | $13,819,590 |
| MILLENNIUM MANAGEMENT LLC | 1% | 403,859 | +25% | 0% | $7,269,462 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.96% | 384,576 | +269% | 0% | $6,923,843 |
| JENNISON ASSOCIATES LLC | 0.95% | 378,507 | +147% | 0% | $6,813,126 |
| NEXTBio Capital Management LP | 0.93% | 372,856 | 0% | 3.1% | $6,711,408 |
| RTW INVESTMENTS, LP | 0.93% | 372,856 | 0% | 0.06% | $6,711,408 |
| Remedium Capital Partners, LLC | 0.9% | 361,250 | 1.4% | $6,502,500 | |
| STATE STREET CORP | 0.79% | 315,587 | +708% | 0% | $5,680,566 |
| AMERIPRISE FINANCIAL INC | 0.76% | 302,568 | 0% | $5,446,224 | |
| Point72 Asset Management, L.P. | 0.75% | 300,000 | 0% | 0.01% | $5,400,000 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.69% | 275,581 | -9.2% | 0% | $4,961,000 |
| MARSHALL WACE, LLP | 0.54% | 214,300 | +6.7% | 0% | $3,857,400 |
| PERCEPTIVE ADVISORS LLC | 0.52% | 206,942 | 0% | 0.06% | $3,724,956 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.47% | 188,803 | 0% | $3,398,454 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 29,113,798 | $524,050,483 | +$71,707,307 | $18.00 | 80 |
| 2026 Q1 | 25,113,643 | $461,268,042 | +$28,504,069 | $18.37 | 59 |
| 2025 Q4 | 23,741,798 | $281,443,423 | +$142,716,069 | $11.86 | 54 |
| 2025 Q3 | 11,318,865 | $134,581,435 | +$2,898,876 | $11.89 | 40 |
| 2025 Q2 | 10,751,740 | $173,532,467 | +$173,532,402 | $16.14 | 29 |